Antipyretic and analgesic drugs are one of the most widely used drugs in the world, and they are also major export products of pharmaceutical raw materials in China, occupying a decisive position in the international market. In 2011, the number of antipyretic analgesics exported in China was 100,771.87 tons, a year-on-year decrease of 24.76%, and the export amount was 454 million US dollars, a year-on-year decrease of 47.66%. The average export unit price was 4.51 USD/kg, a year-on-year decrease of 30.43%.
First, exports to the traditional markets have fallen sharply. The emerging markets are not in 2011. China's antipyretic and analgesic drugs are exported to 126 countries and regions. Asia, Europe and North America are still the main markets for exports, accounting for 77.65 percent of exports. %. Compared with 2010, my exports to the three major markets showed a declining trend. The value of exports to Asia fell by 44.26%, of which: the value of exports to India decreased by 52.21%; the amount of exports to Europe and North America decreased by 53.43% and 57 respectively. %, of which: exports to the 15 European countries fell by 58.86%; exports to the United States decreased by 58.83%; exports to emerging markets in Africa and Latin America also fell by more than 30%, showing that the export of antipyretic drugs in China in 2011 was sluggish .
Second, the operating team decreased year-on-year, and production enterprises are still the main force for exports. In 2011, China exported 610 antipyretic analgesics companies, which was a decrease of 42.67% year-on-year. From the top 20 companies in terms of export volume, 17 companies are involved in production. Enterprises accounted for 74.53% of the export value; only two foreign trade companies accounted for 3.54% of the export value, reflecting the operating advantages of the manufacturers in this product.
From the perspective of the export situation of domestic provinces, the export of antipyretic and analgesic drugs is mainly concentrated in the economically developed regions such as Shandong, Jiangsu and Zhejiang, and Shandong, Jiangsu, Zhejiang, Hebei, and Hubei are the top five exporters of antipyretic analgesics. The export volume of the five provinces and cities accounted for as high as 87.99%, which indicates that the concentration of antipyretic and analgesic products in China is highly concentrated and the development of industrial clusters is significant.
The performance of the three pillars of the four pillar products varied and contributed to the downturn in the export market throughout the year. (1) The market for paracetamol was no longer awaited. The market recovery was still a time when the paraquat fever was the bulk of export commodities for antipyretic analgesics, accounting for 42.91% of export value. Affected by overcapacity and low price competition, in 2011, Paracetamol’s exports to major countries and regions declined in an all-round manner. The amount of exports to Africa fell 26.46% year-on-year, of which, the export amount to Nigeria decreased by 24.31% year-on-year; for ASEAN major countries Thailand and Vietnam The export value decreased by 22.49% and 32.67% respectively year-on-year. Exports to emerging markets Brazil also fell sharply by more than 20%, directly dragging down the trend of anti-pyretic analgesics in 2011. Looking at the export market of paracetamol in recent years, it has always been in the shadow of disorderly competition and low price competition. Industrial advantages have been almost exhausted. Without reshuffling, the market recovery is far from attainable.
(II) The main market advantage of ibuprofen is no longer, which drags down the export market for the whole year. In 2011, the export of ibuprofen to traditional major markets declined significantly. Among them, the export value of the 15 European Union countries fell by 9.44% year-on-year, and the value of exports to India decreased by 22.89% year-on-year. Due to the European debt crisis and the devaluation of the main competitor, the Indian currency, the export price of ibuprofen in China was no longer in the major export markets. Obvious advantages, corporate profits are further squeezed, affecting the company's development potential.
(3) The bright points of the traditional market of Anai and Aspirin are still the same. Latin America and Africa are in the forefront of the export pattern of paracetamol and ibuprofen. In 2011, Aninan and Aspirin showed a good momentum of growth. Anianzhi's export value increased by 10.26% year-on-year, and the average export price increased by 7.00% year-on-year. Aspirin's export value increased by 16.44% year-on-year, and the average export price increased by 7.31% year-on-year. Both of them showed a trend of rising volume and price. According to the statistics of China Customs on emerging markets, the export volume of Anitag to Africa increased 25.17% year-on-year, and the export value to Latin America increased 33.43%. The export value of aspirin to Africa increased by 14.41%, and the export value to Latin America increased 29.59% year-on-year. %. From the above statistics, it can be seen that the export of Analgin and Aspirin has already entered the booming period. The reason is that the strong demand in the mainstream market, the good development of the Latin American economy, and the meticulous cultivation of my exporting companies to the emerging markets are inextricably linked.
Although there are bright spots in the export market for antipyretic analgesics in 2011, the overall situation is worrying. As a traditional bulk export commodity, China's antipyretic analgesics have high competitive advantages in terms of high output, large scale, complete variety, export, and low price in the international market. The main products of antipyretic and analgesic drugs in China are mostly used for export, and their dependence on the international market is very high. Many manufacturing companies have obsolete technology and low grades of products, and it is difficult to enter the high-end market. In the absence of product advantages, enterprises can only rely on Low prices to gain more market share, competition is fierce, the market is tight, tight supply, rising prices - to expand production capacity, supply exceeds demand, prices fall, so cycled, has become the dysentery industry's dysentery development dysentery. The reason: There is a lot to do with the industrial structure of antipyretic analgesics in our country. Over the years, the scale of production in the antipyretic and analgesic industry in China has continuously expanded, the output has doubled, and the advantages of scale have gradually emerged, but technological advantages and quality advantages have emerged. It is yet to be established that the expansion of enterprise scale and production depends on new production lines and blindly expanding production capacity. It has not yet completely freed from the mode of extensive growth. It has not made significant progress in many aspects such as technological improvement and improvement of quality, and only talks about economies of scale and technology. Advantages will inevitably affect the future development of the industry, which will result in a cyclical price war in the industry. The only damage to China will be the anti-pyretic analgesic industry and the natural environment, which will allow foreign countries to take advantage of this. Many years of disorderly market competition have made our products' ability to resist risks in the international market extremely weak. The key to finding a solution to the problem of both the symptoms and the problems lies in the research and development of high-tech and high-quality products. The elimination of the production cycle has entered a recession period. Varieties, extending to high-end, specialty APIs, improving product quality, nurturing well-known brands, and optimizing industrial structure, only in this way can China's antipyretic and analgesic drugs completely out of the market downturn.
First, exports to the traditional markets have fallen sharply. The emerging markets are not in 2011. China's antipyretic and analgesic drugs are exported to 126 countries and regions. Asia, Europe and North America are still the main markets for exports, accounting for 77.65 percent of exports. %. Compared with 2010, my exports to the three major markets showed a declining trend. The value of exports to Asia fell by 44.26%, of which: the value of exports to India decreased by 52.21%; the amount of exports to Europe and North America decreased by 53.43% and 57 respectively. %, of which: exports to the 15 European countries fell by 58.86%; exports to the United States decreased by 58.83%; exports to emerging markets in Africa and Latin America also fell by more than 30%, showing that the export of antipyretic drugs in China in 2011 was sluggish .
Second, the operating team decreased year-on-year, and production enterprises are still the main force for exports. In 2011, China exported 610 antipyretic analgesics companies, which was a decrease of 42.67% year-on-year. From the top 20 companies in terms of export volume, 17 companies are involved in production. Enterprises accounted for 74.53% of the export value; only two foreign trade companies accounted for 3.54% of the export value, reflecting the operating advantages of the manufacturers in this product.
From the perspective of the export situation of domestic provinces, the export of antipyretic and analgesic drugs is mainly concentrated in the economically developed regions such as Shandong, Jiangsu and Zhejiang, and Shandong, Jiangsu, Zhejiang, Hebei, and Hubei are the top five exporters of antipyretic analgesics. The export volume of the five provinces and cities accounted for as high as 87.99%, which indicates that the concentration of antipyretic and analgesic products in China is highly concentrated and the development of industrial clusters is significant.
The performance of the three pillars of the four pillar products varied and contributed to the downturn in the export market throughout the year. (1) The market for paracetamol was no longer awaited. The market recovery was still a time when the paraquat fever was the bulk of export commodities for antipyretic analgesics, accounting for 42.91% of export value. Affected by overcapacity and low price competition, in 2011, Paracetamol’s exports to major countries and regions declined in an all-round manner. The amount of exports to Africa fell 26.46% year-on-year, of which, the export amount to Nigeria decreased by 24.31% year-on-year; for ASEAN major countries Thailand and Vietnam The export value decreased by 22.49% and 32.67% respectively year-on-year. Exports to emerging markets Brazil also fell sharply by more than 20%, directly dragging down the trend of anti-pyretic analgesics in 2011. Looking at the export market of paracetamol in recent years, it has always been in the shadow of disorderly competition and low price competition. Industrial advantages have been almost exhausted. Without reshuffling, the market recovery is far from attainable.
(II) The main market advantage of ibuprofen is no longer, which drags down the export market for the whole year. In 2011, the export of ibuprofen to traditional major markets declined significantly. Among them, the export value of the 15 European Union countries fell by 9.44% year-on-year, and the value of exports to India decreased by 22.89% year-on-year. Due to the European debt crisis and the devaluation of the main competitor, the Indian currency, the export price of ibuprofen in China was no longer in the major export markets. Obvious advantages, corporate profits are further squeezed, affecting the company's development potential.
(3) The bright points of the traditional market of Anai and Aspirin are still the same. Latin America and Africa are in the forefront of the export pattern of paracetamol and ibuprofen. In 2011, Aninan and Aspirin showed a good momentum of growth. Anianzhi's export value increased by 10.26% year-on-year, and the average export price increased by 7.00% year-on-year. Aspirin's export value increased by 16.44% year-on-year, and the average export price increased by 7.31% year-on-year. Both of them showed a trend of rising volume and price. According to the statistics of China Customs on emerging markets, the export volume of Anitag to Africa increased 25.17% year-on-year, and the export value to Latin America increased 33.43%. The export value of aspirin to Africa increased by 14.41%, and the export value to Latin America increased 29.59% year-on-year. %. From the above statistics, it can be seen that the export of Analgin and Aspirin has already entered the booming period. The reason is that the strong demand in the mainstream market, the good development of the Latin American economy, and the meticulous cultivation of my exporting companies to the emerging markets are inextricably linked.
Although there are bright spots in the export market for antipyretic analgesics in 2011, the overall situation is worrying. As a traditional bulk export commodity, China's antipyretic analgesics have high competitive advantages in terms of high output, large scale, complete variety, export, and low price in the international market. The main products of antipyretic and analgesic drugs in China are mostly used for export, and their dependence on the international market is very high. Many manufacturing companies have obsolete technology and low grades of products, and it is difficult to enter the high-end market. In the absence of product advantages, enterprises can only rely on Low prices to gain more market share, competition is fierce, the market is tight, tight supply, rising prices - to expand production capacity, supply exceeds demand, prices fall, so cycled, has become the dysentery industry's dysentery development dysentery. The reason: There is a lot to do with the industrial structure of antipyretic analgesics in our country. Over the years, the scale of production in the antipyretic and analgesic industry in China has continuously expanded, the output has doubled, and the advantages of scale have gradually emerged, but technological advantages and quality advantages have emerged. It is yet to be established that the expansion of enterprise scale and production depends on new production lines and blindly expanding production capacity. It has not yet completely freed from the mode of extensive growth. It has not made significant progress in many aspects such as technological improvement and improvement of quality, and only talks about economies of scale and technology. Advantages will inevitably affect the future development of the industry, which will result in a cyclical price war in the industry. The only damage to China will be the anti-pyretic analgesic industry and the natural environment, which will allow foreign countries to take advantage of this. Many years of disorderly market competition have made our products' ability to resist risks in the international market extremely weak. The key to finding a solution to the problem of both the symptoms and the problems lies in the research and development of high-tech and high-quality products. The elimination of the production cycle has entered a recession period. Varieties, extending to high-end, specialty APIs, improving product quality, nurturing well-known brands, and optimizing industrial structure, only in this way can China's antipyretic and analgesic drugs completely out of the market downturn.
Boronic Acid Affinity Chromatography Resin
NanoMicro has launched a new generation of boronic acid affinity packings in which boronic acid forms a coordination compound with cis-diol for separation and purification. Under alkaline conditions, boronic acid functional group interacts with the cis isomer of a 1,2-diol forming a stable five-membered cyclic adduct of cis-diol molecules and boronic acid on the stationary phase. Under acidic conditions, the adduct ring opens releasing the target molecules. Boronic acid affinity media are employed in the separation and purification of compounds containing cis-diol groups such as glycoproteins, nucleosides, nucleotides, sugars, etc.
Boronic Acid Affinity Chromatography Resin
Suzhou Nanomicro Technology Co., Ltd. , https://www.nanomicro-technology.com